American journal of human geneticsApr 2, 2026

How the FDA's new mechanism guidelines may affect developing personalized gene editing treatments

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

The paper argues that the FDA's plausible mechanism framework may help advance personalized in vivo prime editing for ultra-rare liver-centered genetic disorders.

Evidence

This is a regulatory and proof-of-concept report describing early customizable prime editing studies for 7 urea cycle disorders and a formal FDA meeting about an umbrella-of-umbrellas trial.

Caveat

The abstract reports platform support and regulatory discussion, not clinical efficacy or safety outcomes in patients.

Simplified

In February 2026, the US Food and Drug Administration (FDA) published a draft guidance on a new plausible mechanism framework for the development and approval of individualized therapies for genetic conditions. Here, we report initial proof-of-concept studies supporting a customizable prime editing platform geared to the treatment of 7 urea cycle disorders (UCDs) and other liver-centered disorders, as well as the outcome of a formal meeting with the FDA to discuss the use of the platform in an "umbrella-of-umbrellas" clinical trial including subjects with any of the 7 UCDs. We anticipate our findings will be of interest to academic investigators and industry sponsors who wish to pursue expeditious FDA approvals of therapies for ultra-rare diseases using the plausible mechanism framework.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of interests K.M. is an advisor to Verve Therapeutics, LEXEO Therapeutics, and Capstan Therapeutics; holds equity in Variant Bio; and receives research funding from Nava Therapeutics and Beam Therapeutics. K.M. is also the editor in chief of The American Journal of Human Genetics and was recused from the editorial handling and peer review of this manuscript. R.C.A.-N. is an advisor to Latus Bio and AskBio. M.N.W. and D.L.B. are currently employees of Aurora Therapeutics. O.Y.S. is an employee of RNA Technologies and Therapeutics. B.L.D. holds equity in Latus Bio and is an advisor to or receives research funding from Latus Bio, Carbon Therapeutics, and Seamless Therapeutics. M.-G.A. is an advisor to Afrigen Biologics and Vaccines and holds equity in RNA Technologies and Therapeutics. D.R.L. is an advisor to and/or holds equity in Prime Medicine, Beam Therapeutics, Pairwise Plants, and nChroma Bio. X.W. is an advisor to and receives research funding from Entact Bio, is an advisor to Pluvia Biotech, and receives research funding from Arbor Biotechnologies and Beam Therapeutics.

PubMed

Featured in

CRISPR Gene EditingIssue #31

CRISPR delivered through the nose edits brain genes in mice with ALS mutations

↗

How the FDA's new mechanism guidelines may affect developing personalized gene editing treatments

Abstract

Full Text

Funding

Competing interests

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief